2024
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction
Wong J, Uno H, Tramontano A, Fisher L, Pellegrini C, Abel G, Burstein H, Chun Y, King T, Schrag D, Winer E, Bellon J, Cheney M, Hardenbergh P, Ho A, Horst K, Kim J, Leonard K, Moran M, Park C, Recht A, Soto D, Shiloh R, Stinson S, Snyder K, Taghian A, Warren L, Wright J, Punglia R. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction. JAMA Oncology 2024, 10: 1370-1378. PMID: 39115975, PMCID: PMC11310844, DOI: 10.1001/jamaoncol.2024.2652.Peer-Reviewed Original ResearchFunctional Assessment of Cancer Therapy-BreastPhysical well-beingPostmastectomy radiation therapyImplant-based reconstructionConventional fractionationStudy armsPhysical well-being scoresUS cancer centersLocal-regional disease controlImprove quality of lifeQuality of lifeAs-treated cohortChest wall doseHigher adverse eventsToxic effectsMain OutcomesRandomized clinical trialsPWB scoreUnpaid timePostmastectomy radiationImplant reconstructionRadiation therapyTreatment breaksImplant-basedImprovement changesEndocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
X. C, Suman V, Sanati S, Vij K, Anurag M, Leitch A, Unzeitig G, Hoog J, Fernandez-Martinez A, Fan C, Gibbs R, Watson M, Dockter T, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Rimawi M, Weiss A, Winer E, Hunt K, Perou C, Ellis M, Partridge A, Carey L. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination. JAMA Oncology 2024, 10: 362-371. PMID: 38236590, PMCID: PMC10797521, DOI: 10.1001/jamaoncol.2023.6038.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyBreast cancerWeek 4Neoadjuvant chemotherapyPostmenopausal womenPAM50 subtypesNonluminal tumorsClinical stage II to IIIRate of pathological complete responseClinical trialsHER2)-negative breast cancerPhase 3 randomized clinical trialLuminal B tumorsPathological complete responseLuminal A tumorsEarly-stage diseaseRandomized clinical trialsStage II to IIIAnastrozole armNeoadjuvant anastrozoleTumor Ki67Postmenopausal patientsB tumorsComplete responseA tumors
2018
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2018, 37: 423-438. PMID: 30452337, DOI: 10.1200/jco.18.01160.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine treatmentASCO Clinical Practice GuidelineAdjuvant endocrine therapySecond breast cancerClinical practice guidelinesBreast cancer recurrenceBreast cancerEndocrine treatmentAI treatmentEndocrine therapyExtended therapyCancer recurrencePractice guidelinesHormone receptor-positive breast cancerNode-positive breast cancerNode-negative breast cancerReceptor-positive breast cancerAdjuvant AI therapyNode-positive cancersOverall survival advantageContralateral breast cancerYears of therapyRandomized clinical trialsAromatase inhibitor treatmentAI therapy
2016
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression
Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal Of Clinical Oncology 2016, 34: 1689-1701. PMID: 26884586, DOI: 10.1200/jco.2015.65.9573.Peer-Reviewed Original ResearchConceptsReceptor-positive breast cancerAdjuvant endocrine therapyOvarian suppressionStandard adjuvant therapyEndocrine therapyBreast cancerAdjuvant chemotherapyAdjuvant therapyAromatase inhibitorsClinical Oncology Clinical Practice Guideline UpdateHormone receptor-positive breast cancerEstrogen receptor-positive breast cancerClinical Practice Guideline UpdateStage I breast cancerDisease-free survivalHigh-risk patientsLow-risk patientsI breast cancerSubset of patientsOverall clinical benefitRandomized clinical trialsNode-negative cancersQuality of lifeDistant recurrencePremenopausal women
2014
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2014, 32: 2255-2269. PMID: 24868023, PMCID: PMC4876310, DOI: 10.1200/jco.2013.54.2258.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyHormone receptor-positive breast cancerReceptor-positive breast cancerClinical practice guidelinesAdjuvant tamoxifenEndocrine therapyAromatase inhibitorsBreast cancerPractice guidelinesClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineASCO Clinical Practice GuidelineYears of tamoxifenContralateral breast cancerYears of therapyRandomized clinical trialsBreast cancer recurrenceTreatment of womenOutcomes of interestTamoxifen useAdjuvant therapyASCO guidelinesAdverse eventsTamoxifen treatmentDisease recurrence
2013
A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901
Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal Of Geriatric Oncology 2013, 4: 353-361. PMID: 24472479, PMCID: PMC3910230, DOI: 10.1016/j.jgo.2013.05.004.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsOlder womenStandard chemotherapyClinical trialsProspective comparisonObservational studyBreast cancerNon-metastatic breast cancerOlder cancer populationPre-treatment QoLTherapy side effectsBreast cancer chemotherapyShort-term qualityAdjusted mean increaseQuality of lifeTumor factorsOlder patientsAnthracycline regimensQOL scoresGlobal QoLCancer populationSide effectsGroup physiciansChemotherapyLinear mixed effects models
2011
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, B F. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research 2011, 17: 5170-5178. PMID: 21693655, PMCID: PMC3149770, DOI: 10.1158/1078-0432.ccr-11-0484.Peer-Reviewed Original ResearchConceptsAddition of paclitaxelDoses of doxorubicinOverall survivalP53 protein expressionAdjuvant doxorubicinDose escalationBreast cancerP53 expressionNode-positive breast cancer patientsNode-positive breast cancerEarly-stage breast cancerCycles of cyclophosphamideNode-positive patientsProtein expressionStage II patientsBreast cancer patientsRandomized clinical trialsWorse RFSWorse OSII patientsPredictive factorsWorse prognosisCancer patientsP53 positivityP53 staining
2010
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal Of Clinical Oncology 2010, 28: 2418-2422. PMID: 20368559, PMCID: PMC2881723, DOI: 10.1200/jco.2009.26.4671.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAge FactorsAgedAged, 80 and overAntimetabolites, AntineoplasticBreast NeoplasmsCanadaCapecitabineChemotherapy, AdjuvantDeoxycytidineDrug Administration ScheduleDrug MonitoringFemaleFluorouracilHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMastectomyMedication AdherenceMicro-Electrical-Mechanical SystemsNeoplasm StagingRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsEarly-stage breast cancerBreast cancerCALGB 49907Oral chemotherapyClinical trialsOlder womenPatients age 65 yearsOral adjuvant chemotherapyPill bottle openingsNode-negative diseaseHormone receptor statusRelapse-free survivalRandomized clinical trialsAge 65 yearsMulticenter clinical trialNumber of dosesPercent of participantsLogistic regression modelsAdjuvant chemotherapyProtocol therapyOral therapyStandard chemotherapyMedian ageReceptor statusPatient adherence
2008
NCCN Task Force Report: breast cancer in the older woman.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network 2008, 6 Suppl 4: s1-25; quiz s26-7. PMID: 18597715, DOI: 10.6004/jnccn.2008.2004.Peer-Reviewed Original ResearchConceptsBreast cancerOlder patientsOlder womenBreast cancer treatment recommendationsCancer treatment recommendationsSurgical axillary stagingGeriatric assessment toolsPresence of comorbiditiesMetastatic breast cancerBreast cancer patientsRandomized clinical trialsCurative surgeryNCCN institutionsAxillary stagingEndocrine therapyGeriatric oncologySupportive therapyTask ForceMedical oncologyCancer patientsFunctional statusOncology settingTreatment recommendationsClinical trialsMultidisciplinary panel
2006
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer. Cancer 2006, 106: 2576-2582. PMID: 16703595, DOI: 10.1002/cncr.21919.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantCross-Over StudiesDecision Support TechniquesDisease-Free SurvivalDrug Administration ScheduleFemaleHumansMarkov ChainsMiddle AgedModels, StatisticalModels, TheoreticalNeoplasm StagingOdds RatioPostmenopauseRandomized Controlled Trials as TopicReceptors, ProgesteroneTamoxifenTime FactorsTreatment OutcomeConceptsDisease-free survivalAromatase inhibitorsProgesterone receptorEstrogen receptorOptimal adjuvant endocrine therapyEarly-stage breast cancerAdjuvant endocrine therapyNode-positive groupProgesterone receptor statusRandomized clinical trialsSequential treatmentBreast cancer tumorsAI monotherapyAI therapyBiologic subsetsDFS ratesAdjuvant therapyEndocrine therapyPostmenopausal patientsPostmenopausal womenSequential therapyUpfront treatmentLymph nodesReceptor statusPR expression
2005
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. Journal Of Clinical Oncology 2005, 23: 5178-5187. PMID: 15998905, DOI: 10.1200/jco.2005.02.964.Peer-Reviewed Original ResearchConceptsDisease-free survivalDisease-free survival estimatesAromatase inhibitor monotherapyYears of tamoxifenAromatase inhibitorsSequential therapyBreast cancerInhibitor monotherapyPostmenopausal womenTreatment strategiesHormone receptor-positive breast cancerDisease-free survival ratesDistant disease-free survivalReceptor-positive breast cancerEarly-stage breast cancerSurvival estimatesAdjuvant endocrine therapyAromatase inhibitor therapyCross-over treatmentNode-positive patientsSequential adjuvant therapyPostmenopausal breast cancerRelative risk reductionRandomized clinical trialsSequential treatment strategy